Fecal microbiota transplantation (FMT) for Clostridium difficile infection: Focus on immunocompromised patients

Journal of Infection and Chemotherapy

Volumn 21, Issue 4, 2015, Pages 230-237

  Di Bella, Stefano ^a   Gouliouris, Theodore ^b   Petrosillo, Nicola ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Clostridium difficile; Fecal microbiota transplantation; FMT; Immunocompromised; Microbiota

Indexed keywords

ACTOXUMAB; BEZLOTOXUMAB; METRONIDAZOLE; RIFAXIMIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; BIOLOGICAL THERAPY; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FECAL MICROBIOTA TRANSPLANTATION; FECES MICROFLORA; HUMAN; IMMUNOCOMPROMISED PATIENT; MORBIDITY; MORTALITY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT INFECTION; REVIEW; SYSTEMATIC REVIEW (TOPIC); ADULT; ADVERSE EFFECTS; AGED; CLOSTRIDIUM INFECTIONS; FEMALE; MALE; MIDDLE AGED; PEPTOCLOSTRIDIUM DIFFICILE; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; FECAL MICROBIOTA TRANSPLANTATION; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84930375791     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1016/j.jiac.2015.01.011     Document Type: Review

References (115)

1. Pepin J., Valiquette L., Alary M.E., Villemure P., Pelletier A., Forget K., et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004, 171:466-472.
2. Redelings M.D., Sorvillo F., Mascola L. Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerg Infect Dis 2007, 13:1417-1419.
3. Ananthakrishnan A.N. Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol 2011, 8:17-26.
4. Poutanen S.M., Simor A.E. Clostridium difficile-associated diarrhea in adults. CMAJ 2004, 171:51-58.
5. Magill S.S., Edwards J.R., Bamberg W., Beldavs Z.G., Dumyati G., Kainer M.A., et al. Multistate point-prevalence survey of health care-associated infections. NEngl J Med 2014, 370:1198-1208.
6. Bouza E. Consequences of Clostridium difficile infection: understanding the healthcare burden. Clin Microbiol Infect 2012, 18:5-12.
7. Johnson S. Recurrent Clostridium difficile infection: causality and therapeutic approaches. Int J Antimicrob Agents 2009, 33:S33-S36.
8. Peniche A.G., Savidge T.C., Dann S.M. Recent insights into Clostridium difficile pathogenesis. Curr Opin Infect Dis 2013, 26:447-453.
9. Bibbo S., Lopetuso L.R., Ianiro G., Di Rienzo T., Gasbarrini A., Cammarota G. Role of microbiota and innate immunity in recurrent Clostridium difficile infection. JImmunol Res 2014, 2014:462740.
10. Buffie C.G., Pamer E.G. Microbiota-mediated colonization resistance against intestinal pathogens. Nat Rev Immunol 2013, 13:790-801.
11. He M., Miyajima F., Roberts P., Ellison L., Pickard D.J., Martin M.J., et al. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet 2013, 45:109-113.
12. Hensgens M.P., Goorhuis A., Dekkers O.M., van Benthem B.H., Kuijper E.J. All-cause and disease-specific mortality in hospitalized patients with Clostridium difficile infection: a multicenter cohort study. Clin Infect Dis 2013, 56:1108-1116.
13. See I., Mu Y., Cohen J., Beldavs Z.G., Winston L.G., Dumyati G., et al. NAP1 strain type predicts outcomes from Clostridium difficile infection. Clin Infect Dis 2014, 58:1394-1400.
14. Marsh J.W., Arora R., Schlackman J.L., Shutt K.A., Curry S.R., Harrison L.H. Association of relapse of Clostridium difficile disease with BI/NAP1/027. JClin Microbiol 2012, 50:4078-4082.
15. Kelly C.P., Kyne L. The host immune response to Clostridium difficile. JMed Microbiol 2011, 60:1070-1079.
16. Kyne L., Warny M., Qamar A., Kelly C.P. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001, 357:189-193.
17. Lowy I., Molrine D.C., Leav B.A., Blair B.M., Baxter R., Gerding D.N., et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. NEngl J Med 2010, 362:197-205.
18. Gratwohl A., Baldomero H., Passweg J. Hematopoietic stem cell transplantation activity in Europe. Curr Opin Hematol 2013, 20:485-493.
19. US Organ Procurement and Transplantation Network. Accessible at: . http://optn.transplant.hrsa.gov/.12:370.
20. Alonso C.D., Kamboj M. Clostridium difficile infection (CDI) in solid organ and hematopoietic stem cell transplant recipients. Curr Infect Dis Rep 2014, 16:414.
21. Collini P.J., Kuijper E., Dockrell D.H. Clostridium difficile infection in patients with HIV/AIDS. Curr HIV/AIDS Rep 2013, 10:273-282.
22. Alonso C.D., Marr K.A. Clostridium difficile infection among hematopoietic stem cell transplant recipients: beyond colitis. Curr Opin Infect Dis 2013, 26:326-331.
23. Collini P.J., Bauer M., Kuijper E., Dockrell D.H. Clostridium difficile infection in HIV-seropositive individuals and transplant recipients. JInfect 2012, 64:131-147.
24. Raines D.L., Lopez F.A. Clostridium difficile infection in non-HIV-immunocompromised patients and in HIV-infected patients. Curr Gastroenterol Rep 2011, 13:344-350.
25. Anthony D.M., Reynolds T., Paton J., Rafter L. Serum albumin in risk assessment for Clostridium difficile. JHosp Infect 2009, 71:378-379.
26. Kwok C.S., Arthur A.K., Anibueze C.I., Singh S., Cavallazzi R., Loke Y.K. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 2012, 107:1011-1019.
27. Sanchez T.H., Brooks J.T., Sullivan P.S., Juhasz M., Mintz E., Dworkin M.S., et al. Bacterial diarrhea in persons with HIV infection, United States, 1992-2002. Clin Infect Dis 2005, 41:1621-1627.
28. Alonso C.D., Treadway S.B., Hanna D.B., Huff C.A., Neofytos D., Carroll K.C., et al. Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2012, 54:1053-1063.
29. Munoz P., Giannella M., Alcala L., Sarmiento E., Fernandez Yanez J., Palomo J., et al. Clostridium difficile-associated diarrhea in heart transplant recipients: is hypogammaglobulinemia the answer?. JHeart Lung Transpl 2007, 26:907-914.
30. Kinnebrew M.A., Lee Y.J., Jenq R.R., Lipuma L., Littmann E.R., Gobourne A., et al. Early Clostridium difficile infection during allogeneic hematopoietic stem cell transplantation. PLoS One 2014, 9:e90158.
31. Dallal R.M., Harbrecht B.G., Boujoukas A.J., Sirio C.A., Farkas L.M., Lee K.K., et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002, 235:363-372.
32. Ali M., Ananthakrishnan A.N., Ahmad S., Kumar N., Kumar G., Saeian K. Clostridium difficile infection in hospitalized liver transplant patients: a nationwide analysis. Liver Transpl 2012, 18:972-978.
33. Dubberke E.R., Burdette S.D. Clostridium difficile infections in solid organ transplantation. Am J Transpl 2013, 13:42-49.
34. Anand A., Glatt A.E. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis 1993, 17:109-113.
35. Raza S., Baig M.A., Russell H., Gourdet Y., Berger B.J. Clostridium difficile infection following chemotherapy. Recent Pat Antiinfect Drug Discov 2010, 5:1-9.
36. Kamboj M., Son C., Cantu S., Chemaly R.F., Dickman J., Dubberke E., et al. Hospital-onset Clostridium difficile infection rates in persons with cancer or hematopoietic stem cell transplant: a C3IC network report. Infect Control Hosp Epidemiol 2012, 33:1162-1165.
37. Dubberke E.R., Reske K.A., Yan Y., Olsen M.A., McDonald L.C., Fraser V.J. Clostridium difficile-associated disease in a setting of endemicity: identification of novel risk factors. Clin Infect Dis 2007, 45:1543-1549.
38. Rodemann J.F., Dubberke E.R., Reske K.A., Seo da H., Stone C.D. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 2007, 5:339-344.
39. Schneeweiss S., Korzenik J., Solomon D.H., Canning C., Lee J., Bressler B. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther 2009, 30:253-264.
40. Pant C., Anderson M.P., O'Connor J.A., Marshall C.M., Deshpande A., Sferra T.J. Association of Clostridium difficile infection with outcomes of hospitalized solid organ transplant recipients: results from the 2009 Nationwide Inpatient Sample database. Transpl Infect Dis 2012, 14:540-547.
41. Lee J.T., Kelly R.F., Hertz M.I., Dunitz J.M., Shumway S.J. Clostridium difficile infection increases mortality risk in lung transplant recipients. JHeart Lung Transpl 2013, 32:1020-1026.
42. Gellad Z.F., Alexander B.D., Liu J.K., Griffith B.C., Meyer A.M., Johnson J.L., et al. Severity of Clostridium difficile-associated diarrhea in solid organ transplant patients. Transpl Infect Dis 2007, 9:276-280.
43. Issa M., Ananthakrishnan A.N., Binion D.G. Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis 2008, 14:1432-1442.
44. Guddati A.K., Kumar G., Ahmed S., Ali M., Kumar N., Hari P., et al. Incidence and outcomes of Clostridium difficile-associated disease in hematopoietic cell transplant recipients. Int J Hematol 2014, 99:758-765.
45. Wang M.S., Evans C.T., Rodriguez T., Gerding D.N., Johnson S. Clostridium difficile infection and limitations of markers for severity in patients with hematologic malignancy. Infect Control Hosp Epidemiol 2013, 34:127-132.
46. Cohen S.H., Gerding D.N., Johnson S., Kelly C.P., Loo V.G., McDonald L.C., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010, 31:431-455.
47. Debast S.B., Bauer M.P., Kuijper E.J. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014, 20:1-26.
48. Louie T.J., Cannon K., Byrne B., Emery J., Ward L., Eyben M., et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis 2012, 55:S132-S142.
49. Robinson C.J., Young V.B. Antibiotic administration alters the community structure of the gastrointestinal micobiota. Gut Microbes 2010, 1:279-284.
50. Rea M.C., Dobson A., O'Sullivan O., Crispie F., Fouhy F., Cotter P.D., et al. Effect of broad- and narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon. Proc Natl Acad Sci U S A 2011, 108:4639-4644.
51. McFarland L.V., Elmer G.W., Surawicz C.M. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002, 97:1769-1775.
52. Vardakas K.Z., Polyzos K.A., Patouni K., Rafailidis P.I., Samonis G., Falagas M.E. Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. Int J Antimicrob Agents 2012, 40:1-8.
53. Tickler I.A., Goering R.V., Whitmore J.D., Lynn A.N., Persing D.H., Tenover F.C. Strain types and patterns of Clostridium difficile isolates from the United States, 2011 to 2013. Antimicrob Agents Chemother 2014, 58:4214-4218.
54. Louie T.J., Miller M.A., Mullane K.M., Weiss K., Lentnek A., Golan Y., et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. NEngl J Med 2011, 364:422-431.
55. Cornely O.A., Crook D.W., Esposito R., Poirier A., Somero M.S., Weiss K., et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012, 12:281-289.
56. Cornely O.A., Miller M.A., Louie T.J., Crook D.W., Gorbach S.L. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis 2012, 55:S154-S161.
57. Eyre D.W., Babakhani F., Griffiths D., Seddon J., Del Ojo Elias C., Gorbach S.L., et al. Whole-genome sequencing demonstrates that fidaxomicin is superior to vancomycin for preventing reinfection and relapse of infection with Clostridium difficile. JInfect Dis 2014, 209:1446-1451.
58. Nathwani D., Cornely O.A., Van Engen A.K., Odufowora-Sita O., Retsa P., Odeyemi I.A. Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection. JAntimicrob Chemother 2014, 69:2901-2912.
59. Konijeti G.G., Sauk J., Shrime M.G., Gupta M., Ananthakrishnan A.N. Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis. Clin Infect Dis 2014, 58:1507-1514.
60. Bartsch S.M., Umscheid C.A., Fishman N., Lee B.Y. Is fidaxomicin worth the cost? an economic analysis. Clin Infect Dis 2013, 57:555-561.
61. Johnson S., Schriever C., Galang M., Kelly C.P., Gerding D.N. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007, 44:846-848.
62. Johnson A.P., Wilcox M.H. Fidaxomicin: a new option for the treatment of Clostridium difficile infection. JAntimicrob Chemother 2012, 67:2788-2792.
63. Surawicz C.M., Brandt L.J., Binion D.G., Ananthakrishnan A.N., Curry S.R., Gilligan P.H., et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013, 108:478-498. quiz 99.
64. Mattila E., Arkkila P., Mattila P.S., Tarkka E., Tissari P., Anttila V.J. Rifaximin in the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther 2013, 37:122-128.
65. Larson K.C., Belliveau P.P., Spooner L.M. Tigecycline for the treatment of severe Clostridium difficile infection. Ann Pharmacother 2011, 45:1005-1010.
66. McPherson S., Rees C.J., Ellis R., Soo S., Panter S.J. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum 2006, 49:640-645.
67. Abougergi M.S., Broor A., Cui W., Jaar B.G. Intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis: an observational study and review of the literature. JHosp Med 2010, 5:E1-E9.
68. Abougergi M.S., Kwon J.H. Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review. Dig Dis Sci 2011, 56:19-26.
69. O'Horo J.C., Jindai K., Kunzer B., Safdar N. Treatment of recurrent Clostridium difficile infection: a systematic review. Infection 2014, 42:43-59.
70. Bakken J.S., Borody T., Brandt L.J., Brill J.V., Demarco D.C., Franzos M.A., et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011, 9:1044-1049.
71. Aroniadis O.C., Brandt L.J. Fecal microbiota transplantation: past, present and future. Curr Opin Gastroenterol 2013, 29:79-84.
72. Zhang F., Luo W., Shi Y., Fan Z., Ji G. Should we standardize the 1,700-year-old fecal microbiota transplantation?. Am J Gastroenterol 2012, 107:1755. author reply p -6.
73. Eiseman B., Silen W., Bascom G.S., Kauvar A.J. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958, 44:854-859.
74. Aas J., Gessert C.E., Bakken J.S. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 2003, 36:580-585.
75. Borody T.J., Warren E.F., Leis S., Surace R., Ashman O. Treatment of ulcerative colitis using fecal bacteriotherapy. JClin Gastroenterol 2003, 37:42-47.
76. Petrof E.O., Khoruts A. From stool transplants to next-generation microbiota therapeutics. Gastroenterology 2014, 146:1573-1582.
77. Buffie C.G., Bucci V., Stein R.R., McKenney P.T., Ling L., Gobourne A., et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 2014, 517:205-208.
78. Fraher M.H., O'Toole P.W., Quigley E.M. Techniques used to characterize the gut microbiota: a guide for the clinician. Nat Rev Gastroenterol Hepatol 2012, 9:312-322.
79. Chang J.Y., Antonopoulos D.A., Kalra A., Tonelli A., Khalife W.T., Schmidt T.M., et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. JInfect Dis 2008, 197:435-438.
80. van Nood E., Vrieze A., Nieuwdorp M., Fuentes S., Zoetendal E.G., de Vos W.M., et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. NEngl J Med 2013, 368:407-415.
81. Hamilton M.J., Weingarden A.R., Unno T., Khoruts A., Sadowsky M.J. High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria. Gut Microbes 2013, 4:125-135.
82. Khoruts A., Dicksved J., Jansson J.K., Sadowsky M.J. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. JClin Gastroenterol 2010, 44:354-360.
83. Shankar V., Hamilton M.J., Khoruts A., Kilburn A., Unno T., Paliy O., et al. Species and genus level resolution analysis of gut microbiota in Clostridium difficile patients following fecal microbiota transplantation. Microbiome 2014, 2:13.
84. Grehan M.J., Borody T.J., Leis S.M., Campbell J., Mitchell H., Wettstein A. Durable alteration of the colonic microbiota by the administration of donor fecal flora. JClin Gastroenterol 2010, 44:551-561.
85. Shahinas D., Silverman M., Sittler T., Chiu C., Kim P., Allen-Vercoe E., et al. Toward an understanding of changes in diversity associated with fecal microbiome transplantation based on 16S rRNA gene deep sequencing. MBio 2012, 3.
86. Borody T.J., Khoruts A. Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol 2012, 9:88-96.
87. Cammarota G., Ianiro G., Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. JClin Gastroenterol 2014, 48:693-702.
88. Gough E., Shaikh H., Manges A.R. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011, 53:994-1002.
89. Burke K.E., Lamont J.T. Fecal transplantation for recurrent Clostridium difficile infection in older adults: a review. JAm Geriatr Soc 2013, 61:1394-1398.
90. Postigo R., Kim J.H. Colonoscopic versus nasogastric fecal transplantation for the treatment of Clostridium difficile infection: a review and pooled analysis. Infection 2012, 40:643-648.
91. Schwartz M., Gluck M., Koon S. Norovirus gastroenteritis after fecal microbiota transplantation for treatment of Clostridium difficile infection despite asymptomatic donors and lack of sick contacts. Am J Gastroenterol 2013, 108:1367.
92. Brandt L.J., Aroniadis O.C., Mellow M., Kanatzar A., Kelly C., Park T., et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 2012, 107:1079-1087.
93. Zipursky J.S., Sidorsky T.I., Freedman C.A., Sidorsky M.N., Kirkland K.B. Patient attitudes toward the use of fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection. Clin Infect Dis 2012, 55:1652-1658.
94. Hamilton M.J., Weingarden A.R., Sadowsky M.J., Khoruts A. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol 2012, 107:761-767.
95. Youngster I., Sauk J., Pindar C., Wilson R.G., Kaplan J.L., Smith M.B., et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis 2014, 58:1515-1522.
96. Youngster I., Russell G.H., Pindar C., Ziv-Baran T., Sauk J., Hohmann E.L. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA 2014, 312:1772-1778.
97. Tvede M., Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet 1989, 1:1156-1160.
98. Petrof E.O., Gloor G.B., Vanner S.J., Weese S.J., Carter D., Daigneault M.C., et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut. Microbiome 2013, 1:3.
99. Lawley T.D., Clare S., Walker A.W., Stares M.D., Connor T.R., Raisen C., et al. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog 2012, 8:e1002995.
100. Neemann K., Eichele D.D., Smith P.W., Bociek R., Akhtari M., Freifeld A. Fecal microbiota transplantation for fulminant Clostridium difficile infection in an allogeneic stem cell transplant patient. Transpl Infect Dis 2012, 14:E161-E165.
101. Rubin T.A., Gessert C.E., Aas J., Bakken J.S. Fecal microbiome transplantation for recurrent Clostridium difficile infection: report on a case series. Anaerobe 2013, 19:22-26.
102. Elopre L., Rodriguez M. Fecal microbiota therapy for recurrent Clostridium difficile infection in HIV-infected persons. Ann Intern Med 2013, 158:779-780.
103. Friedman-Moraco R.J., Mehta A.K., Lyon G.M., Kraft C.S. Fecal microbiota transplantation for refractory Clostridium difficile colitis in solid organ transplant recipients. Am J Transpl 2014, 14:477-480.
104. Schunemann M., Oette M. Fecal microbiota transplantation for Clostridium difficile-associated colitis in a severely immunocompromized critically ill AIDS patient: a case report. AIDS 2014, 28:798-799.
105. Ehlermann P., Dosch A.O., Katus H.A. Donor fecal transfer for recurrent Clostridium difficile-associated diarrhea in heart transplantation. JHeart Lung Transpl 2014, 33:551-553.
106. Trubiano J.A., George A., Barnett J., Siwan M., Heriot A., Prince H.M., et al. Adifferent kind of "allogeneic transplant": successful fecal microbiota transplant for recurrent and refractory Clostridium difficile infection in a patient with relapsed aggressive B-cell lymphoma. Leuk Lymphoma 2014, 1-3.
107. Kelly C.R., Ihunnah C., Fischer M., Khoruts A., Surawicz C., Afzali A., et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol 2014, 109:1065-1071.
108. De Leon L.M., Watson J.B., Kelly C.R. Transient flare of ulcerative colitis after fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol 2013, 11:1036-1038.
109. Colman R.J., Rubin D.T. Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. JCrohns Colitis 2014, 8:1569-1581.
110. Ianiro G., Bibbo S., Scaldaferri F., Gasbarrini A., Cammarota G. Fecal microbiota transplantation in inflammatory bowel disease: beyond the excitement 2014, vol. 93(19):e97. Medicine, Baltimore.
111. Quera R., Espinoza R., Estay C., Rivera D. Bacteremia as an adverse event of fecal microbiota transplantation in a patient with Crohn's disease and recurrent Clostridium difficile infection. JCrohns Colitis 2014, 8:252-253.
112. Pathak R., Enuh H.A., Patel A., Wickremesinghe P. Treatment of relapsing Clostridium difficile infection using fecal microbiota transplantation. Clin Exp Gastroenterol 2013, 7:1-6.
113. Duplessis C.A., You D., Johnson M., Speziale A. Efficacious outcome employing fecal bacteriotherapy in severe Crohn's colitis complicated by refractory Clostridium difficile infection. Infection 2012, 40:469-472.
114. Zainah H., Silverman A. Fecal bacteriotherapy: a case report in an immunosuppressed patient with ulcerative colitis and recurrent Clostridium difficile infection. Case Rep Infect Dis 2012, 2012:810943.
115. Wettstein A., Nowak A., Finlayson S., Leis S. Fecal microbiota transplantation (FMT) eradicates Clostridium difficile infection (CDI) in inflammatory bowel disease (IBD). United European Gastroenterol J 2013, A57.